GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 42 Annexure ‘A’ to the Director’s Report Report on Corporate Social Responsibility (CSR) 1. Brief outline on CSR Policy of the Company Healthy communities are the backbone of strong, sustainable societies. However, there are still millions of people without access to basic healthcare in India. Your Company’s approach to corporate social responsibility (CSR) strives to address identified national priorities, improve access and support people in vulnerable communities, either in partnership with credible implementation partners or directly. The CSR policy has been designed in consonance with Section 135 of The Companies Act, 2013 to lay down the guidelines for undertaking CSR initiatives of your Company in accordance with the Companies Rules, 2014 as amended from time to time. 2. Composition of the CSR Committee: Sl. No. Name of Director Designation / Nature of Directorship Number of meetings of CSR Committee held during the year Number of meetings of CSR Committee attended during the year 1. A. N. Roy Chairman, Independent Director 1 1 2. Dr. (Ms.) S. Maheshwari Independent Director 1 1 3. S. Venkatesh Managing Director 1 1 3. Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company. https://india-pharma.gsk.com/media/786327/csr-policy-annexure-3_csr-committee-composition.pdf https://india-pharma.gsk.com/media/733606/csr-policy_revised-310715.pdf https://india-pharma.gsk.com/media/6493/csr-policy-annexure-1_implementation-schedule-and-execution-modalities.pdf 4. Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable (attach the report). Please find the summary report (https://india-pharma.gsk.com/media/7156/summarised-impact-assessment-report.pdf ) for the impact assessment carried out voluntarily for Partnering India to eliminate Lymphatic Filariasis-Albendazole tablets programme. 5. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any Sl. No. Financial Year Amount available for set-off from preceding financial years (in ` lakh) Amount required to be set-off for the financial year, if any (in ` lakh) 1. FY 19-20 1.25 0.00 Total 1.25 0.00 6. Average net profit of the company as per section 135(5): ` 62,684.19 lakh a. Two percent of average net profit of the company as per section 135(5) ` 1253.68 lakh b. Surplus arising out of the CSR projects or programmes or activities of the previous financial years. ` 0.00 c. Amount required to be set off for the financial year, if any ` 0.00 d. Total CSR obligation for the financial year (7a+7b-7c). ` 1253.68 lakh